Alnylam to Webcast Presentations at Upcoming March Investor Conferences

A replay will be available on the Alnylam website within 48 hours after each event.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, February 25, 2020
Information
Tags: 
Biotechnology, Health, Genetics, Pharmaceutical, Automotive, Branches of biology, Biotechnology, Biology, RNA, Gene expression, Alnylam Pharmaceuticals, Therapeutic gene modulation, RNA interference
Geotags: 
United States, Florida, Massachusetts
⚠generated by AI ↴
Summary
Key Points: 
  • A replay will be available on the Alnylam website within 48 hours after each event.
  • Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.
  • Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform.
  • For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn .


Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:

  • Cowen & Company 40th Annual Healthcare Conference on Tuesday, March 3, 2020 at 10:40 am ET at the Marriott Copley Place in Boston
  • Barclays Global Healthcare Conference on Tuesday, March 10, 2020 at 2:35 pm ET at the Loews Miami Beach Hotel in Miami, Florida

A live audio webcast of each presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after each event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), approved in the U.S., EU, Canada, Japan, and Switzerland, and GIVLAARI® (givosiran), approved in the U.S. Alnylam has a deep pipeline of investigational medicines, including five product candidates that are in late-stage development. Alnylam is executing on its “Alnylam 2020” strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam employs over 1,300 people worldwide and is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.

Copyright: 
Copyright Business Wire 2020